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Abstract
Background: The histone methyltransferase G9a has recently been identified as a potential target for epigenetic
therapy of acute myeloid leukemia (AML). However, the effect of G9a inhibition on leukemia stem cells (LSCs),
which are responsible for AML drug resistance and recurrence, is unclear. In this study, we investigated the
underlying mechanisms of the LSC resistance to G9a inhibition.
Methods: We evaluated the effects of G9a inhibition on the unfolded protein response and autophagy in AML and
LSC-like cell lines and in primary CD34+CD38− leukemic blasts from patients with AML and investigated the
underlying mechanisms. The effects of treatment on cells were evaluated by flow cytometry, western blotting,
confocal microscopy, reactive oxygen species (ROS) production assay.
Results: The G9a inhibitor BIX-01294 effectively induced apoptosis in AML cell lines; however, the effect was limited
in KG1 LSC-like cells. BIX-01294 treatment or siRNA-mediated G9a knockdown led to the activation of the PERK/
NRF2 pathway and HO-1 upregulation in KG1 cells. Phosphorylation of p38 and intracellular generation of reactive
oxygen species (ROS) were suppressed. Pharmacological or siRNA-mediated inhibition of the PERK/NRF2 pathway
synergistically enhanced BIX-01294-induced apoptosis, with suppressed HO-1 expression, increased p38 phosphorylation,
and elevated ROS generation, indicating that activated PERK/NRF2 signaling suppressed ROS-induced apoptosis in KG1
cells. By contrast, cotreatment of normal hematopoietic stem cells with BIX-01294 and a PERK inhibitor had no significant
proapoptotic effect. Additionally, G9a inhibition induced autophagy flux in KG1 cells, while autophagy inhibitors
significantly increased the BIX-01294-induced apoptosis. This prosurvival autophagy was not abrogated by PERK/NRF2
inhibition.
Conclusions: PERK/NRF2 signaling plays a key role in protecting LSCs against ROS-induced apoptosis, thus conferring
resistance to G9a inhibitors. Treatment with PERK/NRF2 or autophagy inhibitors could overcome resistance to G9a
inhibition and eliminate LSCs, suggesting the potential clinical utility of these unique targeted therapies against AML.
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Background
Most patients with acute myeloid leukemia (AML) achieve
complete remission with induction chemotherapy; how-
ever, the majority of patients relapse owing to the develop-
ment of drug resistance [1]. Leukemia stem cells (LSCs)
play important roles in the relapse and drug resistance,
which hamper complete cure of the disease [2]. Therefore,
new therapeutic strategies for effective targeting of LSCs
are required to cure AML.
In addition to the recurring cytogenetic and molecular
abnormalities, which have been characterized in AML, re-
cent discoveries have highlighted the major role of dysreg-
ulated epigenetic mechanisms in AML pathogenesis [3, 4].
Studies have indicated that mutations related to DNA
methylation could mediate abnormal self-renewal and dif-
ferentiation of LSCs, suggesting that drugs targeting epi-
genetic enzymes may provide a new AML treatment
option [5–7]. In contrast to genetic changes, epigenetic
modifications are generally reversible, thus providing op-
portunities for targeted treatment with specific inhibitors
[8]. The histone methyltransferase (HMTase) G9a, an epi-
genetic enzyme w ubiquitously expressed in somatic cells,
contributes to the development and progression of various
cancers [9–13]. G9a regulates the transcription of multiple
genes by primarily catalyzing the dimethylation of histone
H3 lysine 9 (H3K9me2) [13] and induces changes in cellu-
lar redox homeostasis, leading to a decrease in reactive
oxygen species (ROS) production [14]. The G9a protein is
accumulated under hypoxic conditions, without an alter-
ation in the levels of G9a transcripts, leading to the epigen-
etic silencing of specific genes in cancer cells [15, 16]. High
levels of G9 expression are associated with unfavorable
clinical outcomes, including disease progression, metasta-
sis, development of stem cell-like characteristics, resistance
to treatment, and poor survival [17, 18]. Inhibition of G9a
suppresses cell proliferation and modulates redox homeo-
stasis, with an increase in ROS generation [14]. It has been
shown that G9a inhibition induces cancer cell death via
intracellular ROS production [19]. Thus, targeting of G9a
has attracted attention as a novel strategy for the treatment
of various types of tumors, including leukemia, which are
characterized by hypoxic regions [20]. Several recent re-
ports have suggested that this HMTase may be a potential
target for epigenetic therapy of AML. Pharmacological and
genetic targeting of G9a has been shown to be effective in
slowing down the AML cell proliferation and reducing the
LSC frequency in a mouse model and human AML cell
lines due to the attenuation of HoxA9-dependent tran-
scription [21–23]. San José-Enériz et al. have reported that
inhibitors of G9a/DNMTs significantly prolong the sur-
vival of AML xenogeneic models [24]. However, the effect
of G9a inhibition on LSCs remains elusive. The tolerance
of LSCs to epigenetic therapies causes treatment failure,
thus hampering the clinical applicability of these therapies,
while inhibition of LSC tolerance is considered a promising
therapeutic strategy.
The endoplasmic reticulum (ER) has a very specific
signaling network system, termed the unfolded protein
response (UPR), which allows cells to adapt to stress or
activate apoptotic signaling when intracellular protective
mechanisms are insufficient [25]. G9a inhibition stimu-
lates caspase-dependent apoptosis and ER stress in hu-
man bladder cancer cells [26]. It has been recently
shown that the PERK pathway, which is one of the main
UPR signaling cascades, acts as a prosurvival ER stress
signal in cancer cells and contributes to the development
of drug resistance [27]. ROS are sensed by stress sensors
in the ER lumen and amplify UPR signaling [28]. PERK
inhibits ROS accumulation by phosphorylating and sta-
bilizing NRF2, which regulates the expression of ROS-
induced phase II detoxification enzymes, such as gluta-
thione S-transferase and HO-1 [29, 30]. The PERK path-
way is a reasonable resistance mechanism candidate,
given that G9a targeting induces cancer cell death
through intracellular ROS production. Autophagy is an-
other cell survival mechanism, which regulates cancer
stem cell properties by contributing to the maintenance
of stemness, induction of recurrence, and development
of resistance to anticancer agents [31].
In this study, we investigated, for the first time, the ef-
fect of G9a inhibition on the PERK pathway and autoph-
agy, contributing to LSC survival, and the potential of
therapeutic targeting of epigenetic mechanisms. We
aimed to elucidate the underlying mechanism of LSC re-
sistance to G9a inhibition and to propose a new thera-
peutic strategy for the elimination of AML LSCs.
Materials and methods
Patients and isolation of AML cells
Human leukemia cells were obtained from diagnostic bone
marrow aspirates of patients with de novo AML, who were
diagnosed at the Yonsei University Severance Hospital
(Seoul, South Korea). This prospective cohort has been
registered at ClinicalTrials.gov (NCT02344966). As AML is
a heterogeneous disease, patients were stratified into risk
groups based on cytogenetic and molecular abnormalities
[32]. To minimize the effect of a heterogeneous response to
treatment, we used samples from patients with cytogeneti-
cally normal AML, without recurrent mutations. After
thawing cryopreserved primary AML cells, CD34+ leukemia
cells were enumerated by flow cytometry (LSR Fortessa; BD
Biosciences) using an APC-labeled antibody against the
myeloid stem cell marker CD34 (BD Biosciences). Samples
from 16 patients with abundant CD34+ leukemia cells (>
57% of mononuclear cells) were selected for the experi-
ments (Additional file 1: Table S1). Human adult CD34+
hematopoietic stem cells (HSCs) were obtained from
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healthy sibling donors who donated HSCs for allogeneic
stem cell transplantation.
Cell culture and chemicals
The AML cell lines U937, MOLM-13, and MV4–11 and
the LSC-like cell lines KG1, KG1a, and Kasumi-1, which
are enriched in cells expressing an LSC phenotype
(CD34+CD38−), were obtained from the American Type
Culture Collection. U937, MOLM-13, MV4–11, KG1,
and Kasumi-1 cells were cultured in RPMI-1640
medium (Gibco Life Technologies), and KG1a cells were
cultured in Iscove’s modified Dulbecco’s medium (Gibco
Life Technologies) supplemented with 10% (v/v) fetal
bovine serum and penicillin (100 U/mL)/streptomycin
(0.1 mg/mL). The G9a inhibitor BIX-01294, the autoph-
agy inhibitors 3-methyladenine (3-MA) and bafilomycin
A1, and the NRF2 inhibitor brusatol were purchased
from Sigma–Aldrich. The PERK inhibitor GSK2606414
was purchased from Selleckchem. Logarithmically grow-
ing cells (2 × 105 cells/mL) were exposed to different
concentrations of BIX-01294 alone or in combination
with the other drugs. The pan-caspase inhibitor Z-VAD-
FMK (R&D Systems) was added to cells prior to the
drug addition in some experiments.
Antibodies
Rabbit polyclonal antibodies against microtubule-associated
protein 1 light chain 3 (LC3) (NB100–2220) and p62
(NBP1–48320) were obtained from Novus Biologicals. A
rabbit polyclonal antibody against poly (ADP-ribose) poly-
merase (PARP; 9542), horseradish peroxidase (HRP)-conju-
gated goat anti-rabbit IgG (7074), and HRP-conjugated goat
anti-mouse IgG (7072) were purchased from Cell Signaling
Technology. A mouse anti-α-tubulin monoclonal antibody
(05–829) was obtained from Merck Millipore. Antibodies
against G9a (B9311; Sigma–Aldrich), phospho (p)-PERK
(3179; Cell Signaling Technology), PERK (5638; Cell Signal-
ing Technology), p-eIF2α (9721; Cell Signaling Technology),
ATF4 (11,815; Cell Signaling Technology), CHOP (SC7351;
Santa Cruz Biotechnology), H3K9me1 (AB8896; Abcam),
H3K9me2 (AB1220; Abcam), H3K27me1 (AB194688;
Abcam), H3K27me2 (9728; Cell Signaling Technology), p-
p38 (9211; Cell Signaling Technology), caspase-3 (9662; Cell
Signaling Technology), caspase-9 (9502; Cell Signaling Tech-
nology), NRF2 (SC722; Santa Cruz Biotechnology), and HO-
1 (SC136960; Santa Cruz Biotechnology) were also used.
Western blotting
Total cell lysates were prepared and analyzed by western
blotting, as described previously [33]. Protein samples were
recovered in sodium dodecyl sulfate (SDS) buffer and
separated by SDS-polyacrylamide gel electrophoresis. The
separated proteins were transferred to a nitrocellulose
membrane and reacted with appropriate primary and
secondary antibodies. Protein bands were detected by en-
hanced chemiluminescence (GE Healthcare). α-Tubulin
was used as a loading control.
Apoptosis assay
The annexin V assay was performed as previously de-
scribed [33] using an LSR Fortessa flow cytometer (BD
Biosciences). To study apoptosis in cell lines, cells were
treated with various concentrations of BIX-01294 or other
drugs for 48 h, then resuspended in annexin V binding
buffer, and incubated with annexin V/FITC (BD Pharmin-
gen) and propidium iodide (PI) or 7-AAD (Beckman
Coulter) for 15min before flow cytometry analysis. To
study apoptosis in LSCs from primary AML cells, cells
were divided into CD34+CD38− fractions by staining with
anti-CD34-APC (BD Biosciences), anti-CD38-PE (BD Bio-
sciences), and 7-AAD for 30min. Data were analyzed
using the FACSuite software (BD Biosciences).
Confocal microscopy
Cells were centrifuged at 800×g onto glass slides, and
coverslips were mounted with aqueous mounting
medium (Dako) containing DAPI (Sigma–Aldrich).
Fluorescence signals were analyzed using a Zeiss LSM
700 laser-scanning confocal microscope. LC3 puncta
were quantified in cells as described [33]. The average
number of LC3 puncta per cell in each treatment group
was estimated by manually counting puncta in 20 ran-
domly selected cells.
Measurement of intracellular generation of ROS
Cells were treated with a given drug alone or in combin-
ation with the antioxidant N-acetylcysteine [NAC; (R)-2-
acetamido-3-sulfanylpropanoic acid; Sigma–Aldrich]
after preincubation with 10 μmol/L dichlorodihydro-
fluorescein diacetate (DCFH-DA; Invitrogen) at 37 °C for
30 min. In addition, 1 × 105 cells were stained with
10 μmol/L DCFH-DA at 37 °C for 30 min, then washed,
and resuspended in Dulbecco’s phosphate-buffered sa-
line (Gibco Life Technologies). The amount of the dihy-
drofluorescein formed was measured by flow cytometry.
Small interfering RNA (siRNA) transfection
siRNAs against PERK, G9a, and NRF2 were purchased
from Qiagen. Leukemia cells (2 × 106) were directly
transfected with siRNA (1 μmol/L) using the V− 01 pro-
gram on an Amaxa nucleofector device (Lonza Cologne
GmbH), according to the manufacturer’s instructions.
After electroporation, the cells were resuspended in a
complete medium and incubated at 37 °C in a humidi-
fied atmosphere containing 5% CO2. Control cells were
transfected with a scrambled siRNA.
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Transfection of green fluorescent protein (GFP)-tagged
LC3
Mammalian GFP-LC3 expression plasmids were de-
scribed previously [33]. Leukemia cells (2 × 106) were
directly transfected with GFP-LC3 cDNA (5 mg), as
described above for siRNA. Immediately after electro-
poration, the cells were resuspended in a complete
medium and incubated at 37 °C in a humidified at-
mosphere containing 5% CO2 for 24 h. Cells express-
ing the GFP-tagged LC3 were used to evaluate
autophagy induction. GFP-LC3 dots in each cell were
counted in at least three separate visual fields.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD)
of at least three independent experiments. Means of two
groups were compared using a two-tailed Student’s
t-test in GraphPad Prism 4.0 (GraphPad Software,
Inc.). P-values of less than 0.05 were considered
significant.
Results
G9a inhibition induced apoptosis in AML cells
The apoptotic response to BIX-01294 treatment differed
among the AML cell lines evaluated. In MOLM-13, MV4–
11, and U937 cells, apoptosis was induced in a
concentration-dependent manner. By contrast, in the AML
LSC-like cell lines KG1, KG1a, and Kasumi-1, which origi-
nated from early myeloid stem cells with more than 70% of
CD34+ cells [34–36], the extent of BIX-01294-induced
apoptosis was lower (Fig. 1a). Among the LSC-like cell
lines, KG1 cells were very insensitive to BIX-01294 treat-
ment; therefore, we used these cells as representative BIX-
01294-resistant cells in further experiments. BIX-01294
suppressed the levels of mono- and dimethylation of H3K9
(H3K9me1 and H3K9me2) and H3K27 (H3K27me1 and
H3K27me2) in a concentration-dependent manner in KG1
cells (Fig. 1b). As cleavage of PARP by activated (cleaved)
caspase-3 is a hallmark of apoptosis, we next assessed
changes in the levels of these molecules in U937 and KG1
cells after treatment with BIX-01294. As expected, cleaved
caspase-3 and PARP were detected after treatment with
Fig. 1 Effects of G9a inhibition in leukemia cells and LSC-like cells. a, Flow cytometry analysis, based on annexin V/PI exclusion, of the fraction of
apoptotic cells after treatment of AML cells and LSC-like cells with BIX-01294 for 48 h. b, H3K9 and H3K27 methylation, analyzed by western
blotting, in KG1 cells treated with various concentrations of BIX-01294 for 24 h. c, Protein expression, analyzed by western blotting with the
indicated antibodies, in KG1 and U937 cells treated with various concentrations of BIX-01294 for 48 h
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BIX-01294 in U937 but not in KG1 cells (Fig. 1c). In U937
cells, BIX-01294 treatment markedly induced phosphoryl-
ation of p38, which is one of the major mammalian
mitogen-activated protein kinases (MAPKs) and is com-
monly involved in ROS-induced apoptosis [37]. By contrast,
p-p38 induction was minimal in KG1 cells (Fig. 1c).
G9a inhibition induced prosurvival PERK signaling in LSC-
like cell lines
Next, we examined whether G9a inhibition activates the
PERK pathway in KG1 cells. BIX-01294 treatment acti-
vated the PERK/eIF2α phosphorylation pathway, with in-
creased ATF4 expression, in KG1 cells (Fig. 2a). Upon
siRNA-mediated G9a knockdown, the level of H3K9me2
effectively decreased, and PERK/eIF2α pathway phos-
phorylation increased (Fig. 2b). To evaluate whether
PERK activation contributes to survival of KG1 cells, we
examined the effect of PERK inhibition by the pharma-
cological inhibitor GSK2606414 or via RNA interference.
We selected the most effective cytotoxic concentration
of GSK2606414 and BIX-01294 to perform a further ex-
periment (Additional file 1: Figure S1). When KG1 cells
were cotreated with 20 μmol/L GSK2606414 and
10 μmol/L BIX-01294, apoptosis was synergistically en-
hanced (P = 0.0003; Fig. 2c). The effects of the PERK in-
hibitor treatment were verified by PERK silencing using
siRNA to confirm that these effects were not due to the
inhibition of any other kinase with the high concentra-
tion of the PERK inhibitor. In KG1 cells transfected with
the PERK siRNA, but not in non-transfected control
cells, BIX-01294 treatment strongly induced apoptosis in
a concentration-dependent manner (Fig. 2d). These re-
sults suggested that the prosurvival PERK pathway was
activated in AML LSCs upon inhibition of the G9a activ-
ity. Similar to our observations in BIX-01294-sensitive
U937 cells (Fig. 1c), in KG1 cells, in which PERK was
inhibited using siRNA (Fig. 2e) or GSK2606414 (Fig. 2f),
BIX-01294 effectively induced p38 phosphorylation and
enhanced the levels of cleaved caspase-3 and PARP. In-
cubation with a pan-caspase inhibitor (Z-VAD-FMK,
20 μmol/L) significantly blocked the apoptosis induction
by GSK2606414 plus BIX-01294 in KG1 cells (Fig. 2g).
Apoptosis was strongly induced upon treatment with
10 μmol/L GSK2606414 in G9a-knockdown cells but not
in non-transfected control KG1 cells (P < 0.0001; Fig. 2h).
Next, we analyzed the effect of PERK pathway inhibition
on BIX-01294-induced apoptosis in KG1a cells, another
LSC-like cell line. BIX-01294 and GSK2606414 synergis-
tically enhanced the apoptosis in KG1a cells (Additional
file 1: Figure S2A; P = 0.0092). siRNA-mediated PERK
knockdown also significantly enhanced the BIX-01294-
induced apoptosis in KG1a cells (Additional file 1: Fig-
ure S2B; P = 0.0021).
PERK inhibition sensitized primary AML LSCs but not
HSCs to BIX-01294
Next, we assessed the effect of cotreatment with BIX-
01294 and GSK2606414 in CD34+-enriched primary
AML LSCs and normal HSCs (Fig. 3 and Additional file
1: Table S1). GSK2606414 enhanced the sensitivity of
CD34+ primary AML cells and significantly enhanced
the BIX-01294-induced cell apoptosis (24.79 ± 1.77% for
BIX-01294 alone and 60.38 ± 3.39% for BIX-01294 plus
GSK2606414; P < 0.0001; Fig. 3a, left panel). Moreover,
the apoptotic cell fraction (annexin V+ 7-AAD+) of
CD34+CD38− primary AML LSCs remarkably increased
upon cotreatment with GSK2606414 and BIX-01294
[20.74 ± 3.88% for BIX-01294 alone and 59.36 ± 6.92%
for BIX-01294 plus GSK2606414; P = 0.0004; Fig. 3a
(right panel) and 3B]. By contrast, no significant proa-
poptotic effect of cotreatment with BIX-01294 and
GSK2606414 was observed in HSCs (Fig. 3c, left panel).
The effect on normal hematopoietic cells, with a
CD34+CD38− immunophenotype, was not significant ei-
ther (Fig. 3c, right panel), suggesting that the PERK-
mediated resistance mechanism may act specifically in
CD34+CD38− LSCs.
PERK signaling attenuated BIX-01294-induced ROS
generation and apoptosis in LSC-like cells
Dichlorodihydrofluorescein diacetate (DCFH-DA), which
is oxidized by cellular ROS, fluorescence measurement
revealed that BIX-01294 treatment alone did not induce
ROS generation in KG1 cells (Fig. 4a). However, ROS ac-
cumulation was observed after cotreatment with 10 μmol/
L BIX-01294 and 20 μmol/L GSK2606414 (Fig. 4a). The
antioxidant N-acetylcysteine (NAC) was used to investi-
gate whether the increase in ROS generation upon
cotreatment was primarily caused cell death. Pretreatment
of KG1 cells with 1mmol/L NAC significantly suppressed
the ROS accumulation (Fig. 4b) and apoptosis (Fig. 4c),
which were induced by cotreatment with BIX-01294 and
GSK2606414. Cleavage of caspase-3 and PARP was not
detected when KG1 cells were treated with BIX-01294
and GSK2606414 after NAC pretreatment (Fig. 4d). These
results indicated that PERK inhibition enhanced LSC sen-
sitivity to BIX-01294-induced ROS generation and
caspase-dependent apoptosis.
G9a inhibition-induced PERK signaling conferred
resistance to LSCs via NRF2/HO-1 activation
We found that BIX-01294 upregulated NRF2, which is a
direct substrate of the PERK kinase, resulting in in-
creased HO-1 expression in KG1 cells (Fig. 5a and b).
siRNA-mediated PERK knockdown effectively abolished
the BIX-01294-mediated upregulation of NRF2 and HO-
1 in KG1 cells (Fig. 5c). HO-1 was downregulated in
NRF2-silenced KG1 cells after BIX-01294 treatment
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Fig. 2 Induction of prosurvival PERK signaling by G9a inhibition in KG1 LSC-like cells. a, Expression of PERK pathway proteins, analyzed by western
blotting, in cells treated with various concentrations of BIX-01294 for 24 h. b, Protein expression, analyzed by western blotting with the indicated
antibodies, in cells transfected with G9a-targeting or control siRNA. c, Flow cytometric analysis of the apoptotic fraction of cells treated with
various concentrations of BIX-01294 in the absence or presence of the PERK inhibitor GSK2606414 (20 μmol/L) for 48 h. d, Apoptosis levels,
determined by flow cytometry, in cells transfected with PERK-targeting or control siRNA and treated with various concentrations of BIX-01294 for
48 h. e, Protein expression, analyzed by western blotting with the indicated antibodies, in PERK/control siRNA-transfected cells after treatment
with 15 μmol/L BIX-01294 for 48 h. f, Protein expression, analyzed by western blotting with the indicated antibodies, in cells treated with BIX-
01294 (10 μmol/L) in the absence or presence of GSK2606414 (20 μmol/L) for 48 h. g, Apoptosis levels, determined by flow cytometry, in cells
pretreated or not with Z-VAD-FMK (20 mmol/L) for 1 h and then treated with BIX-01294 (10 μmol/L) and GSK2606414 (20 μmol/L) for 48 h. h,
Apoptosis levels, determined by flow cytometry, in cells transfected with G9a-targeting or control siRNA and incubated with GSK2606414
(10 μmol/L) for 48 h
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(Fig. 5d), indicating that HO-1 is regulated by the PERK/
NRF2 pathway. Treatment with brusatol, a specific in-
hibitor of NRF2, led to a significant increase in the ex-
tent of BIX-01294-induced apoptosis in a concentration-
dependent manner in KG1 cells (P < 0.0001; Fig. 5e and
Additional file 1: Figure S3). Apoptosis was significantly
enhanced upon treatment of NRF2-knockdown cells but
not control siRNA-transfected or non-transfected KG1
cells with 10 μmol/L BIX-01294 (P = 0.0015; Fig. 5f).
G9a inhibition induced PERK pathway-independent
prosurvival autophagy in LSCs
Next, we evaluated the association between prosurvival
PERK activation and autophagy in KG1 cells. The LC3-
II level increased in KG1 cells after BIX-01294 treatment
(Fig. 6a). After the addition of bafilomycin A1, an inhibi-
tor of autophagosome degradation, the BIX-01294-
induced LC3-II formation was further augmented and
p62 was accumulated, compared with the respective
levels observed with BIX-01294 treatment alone (Fig. 6a),
indicating that BIX-01294 promoted the autophagic flux
in KG1 cells. Microscopic images revealed that BIX-
01294 treatment induced a more than 10-fold increase
in the number of GFP-LC3 puncta in KG1 cells (P <
0.0001; Fig. 6b). The addition of 3-MA or bafilomycin
A1 during treatment with 15 μmol/L BIX-01294 signifi-
cantly increased the level of apoptosis in KG1 cells (3-
MA: P = 0.0033; bafilomycin A1: P = 0.0031; Fig. 6c)
compared with that induced by BIX-01294 treatment
alone, indicating the occurrence of prosurvival autoph-
agy in LSCs. After PERK inhibition using PERK siRNA
(Fig. 6d) or GSK2606414 (Fig. 6e), BIX-01294 treatment
still increased the level of LC3-II and induced p62 deg-
radation. Upon the addition of bafilomycin A1, autopha-
gic flux was demonstrated after PERK silencing and
BIX-01294 treatment, based on the augmented level of
LC3-II (Additional file 1: Figure S4). BIX-01294 treat-
ment after siRNA-mediated NRF2 knockdown increased
Fig. 3 Sensitization of AML LSCs, but not HSCs, to BIX-01294-induced apoptosis via PERK inhibition. a, Flow cytometric analysis, based on
annexin-V/7-AAD exclusion, of apoptotic fractions after treatment of CD34+-enriched primary AML cells from 16 cases with BIX-01294 (5 μmol/L)
in the absence or presence of GSK2606414 (10 μmol/L) for 48 h. Left panel: annexin-V+ 7-AAD+ CD34+ cells; right panel: CD34+CD38− primary
LSCs. b, Flow cytometric analysis, based on annexin-V/7-AAD exclusion, of apoptotic fractions after treatment of normal HSCs from five donors
with BIX-01294 (5 μmol/L) in the absence or presence of GSK2606414 (10 μmol/L) for 48 h. Left panel: annexin-V+ 7-AAD+ CD34+ cells; right panel:
CD34+CD38− primary HSCs. c, Representative scatter plot of CD34+-enriched primary AML cells
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the level of LC3-II and resulted in p62 degradation
(Fig. 6f). These results indicated that BIX-01294 induced
prosurvival autophagy even after PERK inhibition, sug-
gesting that autophagy induction occurred independ-
ently of the PERK pathway. When we combined
treatment with 3-MA or bafilomycin A1 with PERK in-
hibition using GSK2606414 (Fig. 6g) or PERK siRNA
(Fig. 6h), 10 μmol/L BIX-01294 markedly increased apop-
tosis of KG1 cells, compared with the levels observed with
combination treatments with 10 μmol/L BIX-01294 and
either 3-MA, bafilomycin A1, GSK2606414, or PERK
siRNA.
Discussion
LSCs are responsible for the initiation, progression, and
therapeutic resistance of leukemia. G9a has emerged as
a promising target for cancer stem cells [18]. However,
the effect of G9a inhibition on LSCs, which develop re-
sistance to therapy via several cell survival mechanisms,
has not been explored. To our knowledge, this is the
first study demonstrating that resistance to G9a inhib-
ition occurs through PERK/NRF2 signaling and autoph-
agy activation in AML LSC-like cells. G9a inhibition by
either BIX-01294 or siRNA triggered activation of the
prosurvival PERK/NRF2 pathway in LSC-like cells.
Fig. 4 Effects of PERK inhibition on BIX-01294-induced ROS generation and ROS-induced apoptosis of KG1 LSC-like cells. a, Intracellular ROS
generation, measured by flow cytometry, in cells treated with BIX-01294 (10 μmol/L) in the absence or presence of GSK2606414 (20 μmol/L) for
16 h. b, ROS generation after cotreatment of cells with BIX-01294 (10 μmol/L) and GSK260641 (20 μmol/L) with/without preincubation with NAC
(1 mmol/L) for 1 h. c, Apoptosis levels, determined by flow cytometry, after cotreatment of cells with BIX-01294 (10 μmol/L) and GSK2606414
(20 μmol/L) for 48 h, with/without preincubation with NAC (1 mmol/L) for 1 h. d, Protein expression, analyzed by western blotting with the
indicated antibodies, after cotreatment of cells with BIX-01294 (10 μmol/L) and GSK2606414 (20 μmol/L) for 48 h, with/without preincubation with
NAC (1 mmol/L) for 1 h
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Meanwhile, inhibition of PERK/NRF2 signaling remark-
ably enhanced the G9a-induced apoptosis of LSC-like
cell lines and primary CD34+CD38− blasts from patients
with AML. Autophagy inhibition also significantly in-
creased the level of apoptosis, which was induced by
G9a inhibition in LSC-like cells.
This study revealed that LSC-like cells developed re-
sistance to G9a inhibition, while apoptosis was effect-
ively induced in leukemia cell lines. Although a G9a
inhibitor effectively inhibited G9a in a concentration-
dependent manner, as reflected by the reduced
H3K9me2 level in KG1 cells, the inhibitor showed a
low efficacy in inducing apoptosis. p38 was strongly
phosphorylated in U937 cells, in which apoptosis was
significantly induced upon G9a inhibition. By contrast,
p38 phosphorylation was very weak in KG1 cells.
Accumulated ROS activate protein kinase B (also
known as Akt) and apoptosis signal-regulating kinase
1 (ASK1), a serine/threonine kinase that was initially
discovered as a MAPK kinase kinase in the p38
MAPK signaling cascade [38]. ASK1 activation results
in downstream activation of the p38 MAPK and,
eventually, in apoptosis [39, 40]. In this study, sup-
pression of the PERK activation by G9a inhibition in
KG1 cells resulted in increased levels of p-p38, which,
in turn, enhanced apoptosis, suggesting ROS involvement
in this process. We also observed that cotreatment with
G9a and PERK inhibitors resulted in increased ROS gen-
eration, in contrast to the treatment with the G9a inhibi-
tor alone. After pretreatment with 1mmol/L NAC,
simultaneous inhibition of G9a and PERK did not induce
apoptosis of KG1 cells. This finding demonstrated that the
Fig. 5 Prosurvival PERK/NRF2/HO-1 activation in KG1 LSC-like cells upon G9a inhibition. a, NRF2 and HO-1 expression, analyzed by western
blotting, after cell treatment with various concentrations of BIX-01294 for 24 h. b, NRF2 and HO-1 expression, analyzed by western blotting, after
cell treatment with BIX-01294 (10 μmol/L) for different periods. c, Protein expression, analyzed by western blotting with the indicated antibodies,
in PERK siRNA-transfected and non-transfected cells after treatment with BIX-01294 (15 μmol/L) for 48 h. d, Protein expression, analyzed by
western blotting with the indicated antibodies, in NRF2 siRNA-transfected and non-transfected cells after treatment with BIX-01294 (10 μmol/L)
for 48 h. e, Apoptotic fractions, measured using flow cytometry, after cell treatment with BIX-01294 (10 μmol/L) in the absence or presence of the
NRF2 inhibitor brusatol (0.5 μmol/L) for 48 h. f, Apoptosis levels, determined by flow cytometry, after treatment of NRF2 siRNA- or control siRNA-
transfected cells with different concentrations of BIX-01294 for 48 h
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Fig. 6 PERK pathway-independent induction of prosurvival autophagy in KG1 LSC-like cells upon G9a inhibition. a, LC3-I/II and p62 expression,
analyzed by western blotting, after cell treatment with BIX-01294 (15 μmol/L) in the absence or presence of bafilomycin A1 (BafA1) for 24 h. b,
Confocal microscopy images of GFP-LC3-transfected cells after treatment with BIX-01294 (5 μmol/L). c, Apoptotic fractions, measured using flow
cytometry, after cell treatment with BIX-01294 (15 μmol/L) in the absence or presence of the autophagy inhibitor 3-MA (5 mmol/L) or BafA1 (2
nmol/L) for 48 h. d, Protein expression, analyzed by western blotting with the indicated antibodies, after treatment of PERK siRNA-transfected and
non-transfected cells with BIX-01294 (15 μmol/L) for 48 h. e, Protein expression, analyzed by western blotting with the indicated antibodies, after
cell treatment with BIX-01294 (10 μmol/L) in the absence or presence of GSK2606414 (20 μmol/L) for 48 h. f, Protein expression, analyzed by
western blotting with the indicated antibodies, after treatment of NRF2 siRNA-transfected and non-transfected cells with BIX-01294 (10 μmol/L)
for 48 h. g, Levels of apoptosis, evaluated by flow cytometry, after cell treatment for 48 h with BIX-01294 (10 μmol/L) in the absence or presence
of the PERK inhibitor GSK2606414 (10 μmol/L) or the autophagy inhibitor 3-MA (5 mmol/L), or BafA1 (2 nmol/L). h, Levels of apoptosis, evaluated
by flow cytometry, after treatment of PERK siRNA- or control siRNA-transfected cells with BIX-01294 (10 μmol/L) in the absence or presence of 3-
MA (5 mmol/L) or BafA1 (2 nmol/L)
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activation of the PERK pathway was a critical defense
regulatory mechanism against ROS accumulation, which
induces apoptosis via p38 MAPK signaling.
To induce death by cotreating LSC-like cells, which sur-
vived despite G9a inhibition, with the PERK inhibitor
GSK2606414, a high (e.g., 20 μmol/L) concentration of the
inhibitor was required in this study. Because GSK2606414,
as all kinase inhibitors, is directed to the ATP-binding site
of PERK, it shows off-target kinase inhibitor effects. To
confirm that the effects of GSK2606414 at the high con-
centration were not due to the inhibition of any other kin-
ase nor to off-target effects, PERK was also silenced with
siRNA. Despite the subnanomolar IC50 of GSK2606414,
higher concentrations of GSK2606414 were needed to
completely block PERK autophosphorylation under condi-
tions of extreme ER stress [41]. Presumably, PERK activa-
tion was extremely induced by ROS when G9a was
inhibited in LSC-like cells, and therefore, a higher concen-
tration of the PERK inhibitor was required to suppress the
PERK pathway.
Whereas PERK signaling is largely mediated through
the eIF2α/ATF4 pathway, the transcription factor NRF2 is
also a direct substrate of the PERK kinase [42], with ATF4
interacting with NRF2 to regulate HO-1 expression. Dur-
ing ER stress, PERK phosphorylates NRF2, leading to its
nuclear translocation, and contributes to cellular redox
homeostasis by upregulating the antioxidant HO-1 [42,
43]. Consistently, we found that G9a inhibition induced
PERK phosphorylation, leading to eIF2α/ATF4 and NRF2
activation in LSC-like cells. In addition, our data showed
that the PERK/NRF2 pathway was activated, leading to
the upregulation of HO-1 expression, thus protecting
LSC-like cells against oxidative stress.
Cotreatment with G9a and PERK inhibitors synergis-
tically enhanced apoptosis of LSCs, while sparing HSCs,
which respond to oxidative stress differently than LSCs
do [44]. Low levels of ROS are required to maintain qui-
escence and stemness of HSCs, whereas increased ROS
levels trigger myeloid progenitor differentiation of these
cells [45]. In contrast, LSCs show peculiar metabolic
properties, being more dependent on oxidative respir-
ation than on glycolysis; moreover, LSCs are more sensi-
tive to oxidative stress than HSCs are [44]. The different
responses to G9a inhibition-induced ROS may be ex-
plained by these characteristics of LSCs and HSCs.
These results suggest that the ROS accumulation, in-
duced by targeting PERK/NRF2, opens up a possibility
of selective LSC eradication. Rushworth et al. have re-
ported that NRF2 knockdown significantly augmented
the chemotherapy-induced reduction in colony forma-
tion by AML cells [46], which may be explained by
our findings.
Anticancer therapies commonly lead to the activation
of prosurvival autophagy, allowing cancer cells to
overcome cytotoxicity or other treatment-induced
stresses [47]. We previously reported that autophagy in-
duction was involved in the resistance of AML cells to
cytosine arabinoside [48] and LSCs to a bromodomain
and extraterminal domain inhibitor [33], which provided
evidence that autophagy could act as a prosurvival
mechanism in AML. Consistently, in this study, we ob-
served a protective autophagic response in LSC-like cells
after BIX-01294 treatment. The addition of autophagy
inhibitors to G9a inhibitor treatment resulted in a sig-
nificant increase in the level of apoptosis of AML LSC-
like cells. Thus, our findings indicate that autophagy in-
duction is one of the critical mechanisms involved in
BIX-01294 resistance in AML LSCs. Previous studies
have shown that the autophagy pathway is induced in
response to G9a inhibitor treatment in breast, bladder,
and colon cancers [19, 26, 49]. These studies suggested
that autophagy induction by G9a inhibition functioned
as a prodeath and not prosurvival signal in cancer cells,
while the opposite was observed in LSCs in our study.
Cancer cells have heterogeneous properties, depending
on the cell type, and thus, either induction or inhibition
of autophagy can provide therapeutic benefits [50].
ER stress is considered to activate autophagy via
UPR-mediated transcriptional upregulation of compo-
nents of the autophagic machinery and the modula-
tion of LC3 [51]. Induction of the PERK pathway
activates an ER stress-induced autophagic mechanism,
which plays an important role in cell survival [52].
Alterations in the expression/activity of key UPR
components (i.e., IRE1, PERK, and related transduc-
ers) and induction of prosurvival autophagy (in an
IRE1- and PERK-dependent manner) have been re-
ported in tumor cells [51]. However, when we investi-
gated the interaction between the PERK pathway and
autophagy by evaluating the expression of autophagy-
associated molecules after PERK/NRF2 inhibition, we
found that G9a inhibition-induced autophagy and
PERK/NRF2 were not interrelated in LSCs. Further
investigation of the regulatory mechanism of prosurvi-
val autophagy is needed to improve our knowledge of
the mechanism of resistance of AML LSCs to G9a
inhibition.
Conclusions
This is the first study providing evidence that inhibition
of the ROS-activated PERK/NRF2 pathway and of ER
stress-independent autophagy augments caspase-
dependent apoptosis, which is induced by G9a inhib-
ition in LSCs. Based on these findings, we propose a
model to explain the resistance of LSCs to G9a inhib-
ition (Fig. 7). These results suggest that combining
PERK/NRF2 and autophagy inhibition with G9a-
targeting treatment may be a useful approach for LSC
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elimination, potentially leading to curative therapies for
AML. Differential expression of or mutations in genes
associated with PERK/NRF2 activation may serve as
prognostic markers in AML. However, future studies
are needed to determine how these cellular processes
are differentially regulated in LSCs. Additionally,
in vivo studies are needed to confirm the effects of the
combination of PERK/NRF2 pathway or autophagy in-
hibition with that of G9a in LSCs. Our findings may
provide valuable information on the underlying mo-
lecular mechanism of resistance of LSCs to G9a inhib-
ition, along with potential therapeutic targets to
overcome AML resistance to G9a inhibitors and to
eradicate LSCs.
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